Pharma-Money

Big Pharma’s exorbitant cancer drug prices are due to corrupt monopolies, not development costs, study shows

Authors of a new report published online in Mayo Clinic Proceedings say that dramatically higher prices for cancer medications are beginning to have a negative effect on patient care in the U.S., as well as the American health care system overall. “Americans with cancer pay 50 percent to 100 percent more for the same patented drug than patients in other …